Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 305 participants.
Also called NCT05593575
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 305 participants
- Registry
-
NCT05593575
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT05593575. Randomized; double masking; primary purpose treatment. Start 2023-03-22 (actual); primary completion 2024-12-31 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease
- Condition
- Diabetic Kidney Disease
- Intervention (Drug)
- SPH3127+SPH3127matching placebo+valsartan matching placebo
- Intervention (Drug)
- SPH3127+SPH3127matching placebo+valsartan matching placebo
- Intervention (Drug)
- SPH3127+valsartan matching placebo
- Intervention (Drug)
- SPH3127 matching placebo+valsartan
- Lead sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Record details
- Record id
cardio:ct-nct05593575- Content hash
69d516062a0782ee142435d9a18ddcd8406f1e8f6fe89677df24a30c6be0ed40